Breaking News

mRNA COVID-19 Vaccines Deliver Substantial Protection

April 2, 2021 • 3:01 pm CDT
(Precision Vaccinations)

The US Centers for Disease Control and Prevention (CDC) published a new study in the Morbidity and Mortality Weekly Report on April 2, 2021 that says 'interim vaccine effectiveness findings for both Pfizer-BioNTech and Moderna mRNA vaccines in real-world conditions complement and expand upon the vaccine effectiveness estimates from recent studies.

And these experimental COVID-19 vaccines demonstrate that current vaccination efforts result in substantial preventive benefits among working-age adults. They reinforce the CDC’s recommendation of full 2-dose immunization with mRNA vaccines.

This CDC study reviewed the findings of prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers who completed weekly SARS-CoV-2 testing for 13 consecutive weeks.

The eight locations that shared a common protocol and methods were Phoenix, Tucson, and other areas in Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah.

Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after the second dose) was 90% against the SARS-CoV-2 coronavirus.

infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after the first dose) before the second dose) was 80%.

It takes about two weeks following each dose of vaccine for the body to produce antibodies that protect against infection. As a result, people are considered “partially vaccinated” two weeks after their first dose of mRNA vaccine and “fully vaccinated” two weeks after their second dose.

'COVID-19 vaccination is recommended for all eligible persons, which currently varies by location in the USA,' said the CDC.

'The scientific rigor of these findings is enhanced by its prospective design and the participants’ very high adherence to weekly specimen collection. As the study progresses, viruses will be genetically characterized to examine the viral features of breakthrough infections. Given that there is uncertainty related to the number of days required to develop immunity postvaccination, future research examining vaccine effectiveness at different intervals is warranted, concluded this study.

All study authors completed and submitted the International Committee of Medical Journal Editors form to disclose potential conflicts of interest. No substantial industry conflicts of interest were disclosed.